

# Balaxi Pharmaceuticals Limited

January 25, 2024

To,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

**NSE Symbol: BALAXI**

**Subject: Conversion of Warrants and Allotment of Equity Shares**

Dear Sir/Madam,

This is in reference to our letter dated October 11, 2022, regarding allotment of Convertible Warrants on Preferential Basis and pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We hereby inform you that seven (7) of the convertible warrant holders to whom the warrants were allotted on October 11, 2022, have exercised their right of conversion and applied for conversion of the warrants into equity shares. Consequently, the Board of Directors vide circular resolution passed today i.e. January 25, 2024, have approved the allotment of 1,04,050 (One Lakh Four Thousand Fifty) Equity Shares at an issue price of Rs. 451/- (Rupees Four Hundred and Fifty-One only) each i.e., of the face value of Rs. 10/- each and at a premium of Rs. 441/- each to the warrant holders specified here-in-below:

| Sno. | Name of the Allottee(s) | Category of the Allottee(s) | Sub - Category of the Allottee(s) | Total Number of Warrants held | Number of warrants applied for conversion into Equity Shares | Number of Equity Shares allotted upon conversion of warrants |
|------|-------------------------|-----------------------------|-----------------------------------|-------------------------------|--|--|
| 1    | Kunal Bhakta            | Public                      | Independent Director              | 2,00,000                      | 67,000   | 67,000   |
| 2    | Faisal Siddiqui         | Public                      | Individual                        | 12,500                        | 12,500   | 12,500   |
| 3    | Meenakshi Agarwal       | Public                      | Individual                        | 7,300                         | 7,300  | 7,300  |
| 4    | Sheela Kothari          | Public                      | Individual                        | 6,250                         | 6,250  | 6,250  |
| 5    | Kamal Ladiwala          | Public                      | Individual                        | 11,000                        | 5,500  | 5,500  |
| 6    | Gryphon Ventures LLP    | Public                      | Limited Liability Partnership     | 15,000                        | 5,000  | 5,000  |

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

# Balaxi Pharmaceuticals Limited

|              |               |        |            |                 |                 |                 |
|--------------|---------------|--------|------------|-----------------|-----------------|-----------------|
| 7            | Sunny Purohit | Public | Individual | 1,000           | 500             | 500             |
| <b>Total</b> |               |        |            | <b>2,53,050</b> | <b>1,04,050</b> | <b>1,04,050</b> |

The allotment has been made on receipt of the balance exercise price payable of Rs. 338.25/- per warrant (being an amount equivalent to 75% of the warrant exercise price of Rs. 451/- per warrant), aggregating to Rs. 3,51,94,912.50/- (Three Crore Fifty-One Lakhs Ninety-Four Thousand Nine Hundred and Twelve Rupees and Fifty Paise only).

Consequent to the allotment of above-mentioned equity shares, the paid-up capital of the Company has increased to Rs. 10,33,42,500/- (Rupees Ten Crores Thirty-Three Lakhs Forty-Two Thousand Five Hundred only) comprising of 1,03,34,250 (One Crore Three Lakhs Thirty Four Thousand Two Hundred and Fifty) Equity Shares of face value Rs. 10/- (Rupees Ten only) each.

This intimation will also be available on the Company's Website at [www.balaxipharma.in](http://www.balaxipharma.in).

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

**Udayan Shukla**

*(Company Secretary and Compliance Officer)*

*Membership No.: F11744*

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)